Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733431 | 0.89 | BACE1 (0.44) | BACE1RAB9AGRM4CARM1PRMT6 | |
| SCHEMBL4734100 | 0.79 | MAPK8 (0.46) | RAB9AHPGD | |
| SCHEMBL7367004 | 0.77 | SLC22A12 (0.47) | RAB9AGRM4SLC22A12HAO1 | |
| SCHEMBL29719546 | 0.75 | KMT2A (0.56) | BACE1CYP1A2CYP2C9CYP2C19ALOX5AP | |
| SCHEMBL7367307 | 0.74 | AR (0.50) | RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10955865 | 0.74 | KDM4E (0.53) | BACE1RAB9ASLC22A12CYP1A2CYP2C19 | |
| SCHEMBL4731989 | 0.73 | RAB9A (0.37) | RAB9ACARM1PRMT6FEN1 | |
| SCHEMBL23657444 | 0.73 | KMT2A (0.57) | RAB9AGRM4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3287923 | 0.73 | ALOX5AP (0.43) | BACE1RAB9ASLC22A12CYP1A2CYP2C19 | |
| SCHEMBL7366258 | 0.72 | L3MBTL1 (0.52) | RAB9ASLC22A12P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008057280-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | TIE1, FLT4, CDK1 | BACE1 1949/4885RAB9A 3516/4885GRM4 2201/4885 |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | TIE1, AURKB, TEK | BACE1 2886/4885RAB9A 3497/4885GRM4 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.